Immunohistological study of NM 23 and C-erbB-2 expression in primary tumor and metastases of colorectal adenocarcinoma

Bulletin of Experimental Biology and Medicine

Volumn 135, Issue 5, 2003, Pages 489-494

  Delektorskaya, V V ^a   Perevoshchikov, A G ^a   Kushlinskii, N E ^a  

^a N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

Author keywords

Adenocarcinoma; c erbB 2; Colon; Immunohistochemistry; nm 23

Indexed keywords

ONCOPROTEIN; PROTEIN NM 23; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; COLORECTAL CANCER; COLORECTAL CARCINOMA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; INCIDENCE; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROGNOSIS; PROTEIN EXPRESSION; TUMOR;

EID: 0242268959     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024979728751     Document Type: Article

References (10)

1. DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study
2. C. R. Berney, R. J. Fisher, J. Yang, et al., Ann. Surg., 230, No. 2, 179-184 (1999).
3. C. R. Berney, J. Yang, R. J. Fisher, et al., Oncol. Res., 10, No. 1, 47-54 (1998).
4. P. J. Crowe, J. Yang, and C. R. Berney, World J. Surg., 25, No. 8, 996-1001 (2001).
5. A. Dursun, N. Akyurek, N. Gunel, and D. Yamac, Pathology, 34, No. 5, 427-432 (2002).
6. A. Forte, A. D'Urso, and S. Gallinarol., G. Chir., 23, No. 3, 61-63 (2002).
7. J. Hayer, M. Engel, M. Seifent, et al., Anticancer Res., 21, No. 4A, 2821-2825 (2001).
8. J. C. Lee, S. T. Wong, N. H. Chow, et al., Eur. J. Cancer, 38, No. 8, 1065-1071 (2002).
9. W. Muller, A. Schneiders, G. Hommel, et al., Cancer, 1583, No. 12, 2481-2487 (1998).
10. M. Sarris and C. S. Lee, Eur. J. Surg. Oncol., 27, No. 2, 170-174 (2001).